Use of home oxygen is associated with reduced physical function in patients with either COPD or idiopathic pulmonary fibrosis.
Routine use of supplemental oxygen does not reduce one-year all-cause mortality versus ambient air
Researchers find oxygen therapy does not improve quality of life, forestall hospitalization, lengthen lives
Shortly after an EUA was issued, Genentech announced that tocilizumab (marketed under the brand name Actemra) was in shortage.
The EUA was issued based on 4 randomized controlled clinical trials that evaluated the efficacy and safety of Actemra in more than 5500 hospitalized patients with COVID-19.
Drugs in the Pipeline
Findings showed that the trial did not meet statistical significance on the primary endpoint.
Investigators evaluated the relationship between atopic dermatitis and frequency of severity markers in patients hospitalized with COVID-19.
Intubation or death, disease worsening similar for tocilizumab, placebo in hospitalized patients.